Nilai Total Perusahaan: cellectis.com (CLLS)

Cellectis S.A. (CLLS) leverages unique TALEN technology to create affordable donor cell products, which provides the company with significant pricing power. A team of top geneticists operates in state-of-the-art laboratories, striving to defeat oncology. This price action on GURU.Markets illustrates an Enterprise Value of 7.34. Meanwhile, the binary risks associated with a narrow development profile are mitigated by large-scale partnerships with pharmaceutical behemoths.

For Cellectis S.A. (CLLS), the enterprise value reflects the market valuation of the potential for scalable genome editing, combining market capitalization with net debt (liabilities minus cash). By analyzing the enterprise value trend, an investor sees the actual buyout price of the business, where high R&D efficiency and the versatility of cell products determine the fundamental attractiveness of the capital relative to current debt risks.